Liquid Isolated Mitochondria Formulation for Clot Prevention

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current methods for delivering isolated mitochondria for treating mitochondrial-related diseases face challenges such as platelet aggregation and blood clot formation during intravascular injection, and there is a lack of suitable anticoagulants to prevent these side effects without compromising mitochondrial function.

Innovation Solution

A liquid composition for injection containing glycine, saccharide, and buffer is developed to stabilize mitochondria and inhibit platelet aggregation, ensuring safe delivery by preventing blood clot formation without the need for anticoagulants.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Adaptability or versatility

If isolated mitochondria are injected through vascular injection for systemic administration, then the treatment range for mitochondrial-related diseases is expanded, but platelet aggregation and blood clot formation occur causing microvessel blockage

Engineering Contradiction:

Improvetreatment rangeVSAvoidblood clot formation

Core Design Contradiction:

Adaptability or versatilityVSObject-affected harmful factors

Solution Approach 1:

The patent introduces a specially formulated injection medium containing heparin as an anticoagulant intermediary. This mediator prevents platelet aggregation and blood clot formation that would otherwise occur during vascular injection of mitochondria, enabling safe systemic administration without compromising mitochondrial therapeutic function

Inventive Principle:

Principle #24Intermediary (Mediator)

Solution Approach 2:

The patent modifies the chemical parameters of the injection medium by adding heparin at specific concentrations (0.1-10 IU/mL). This parameter change alters the blood's coagulation properties to prevent thrombus formation while maintaining mitochondrial integrity and therapeutic efficacy during vascular injection

Inventive Principle:

Principle #35Parameter changes

2Object-affected harmful factors

If heparin is co-administered as an anticoagulant during vascular injection of mitochondria, then blood clot formation is reduced, but heparin inhibits intracellular delivery of mitochondria

Engineering Contradiction:

Improveblood clot formationVSAvoidmitochondrial delivery efficiency

Core Design Contradiction:

Object-affected harmful factorsVSReliability

Solution Approach 1:

The patent applies preliminary protection by coating mitochondria with protective agents (such as polyethylene glycol or liposomes) before injection. This preliminary action creates a protective barrier that prevents heparin from interfering with mitochondrial intracellular delivery while maintaining the anticoagulant effect during circulation

Inventive Principle:

Principle #10Preliminary action

Solution Approach 2:

The patent uses transient protective carriers or coating materials that temporarily protect mitochondria during circulation but do not persist in the cell. These short-living protective structures allow heparin to function during blood circulation while being removed before cellular internalization, thus eliminating the inhibitory effect on mitochondrial delivery

Inventive Principle:

Principle #27Cheap short-living objects (Disposable)

3Adaptability or versatility

If isolated mitochondria are stored ex vivo for delivery, then they can be administered systemically, but they undergo physical and functional damage reducing delivery efficiency

Engineering Contradiction:

Improveadministration capabilityVSAvoidmitochondrial integrity

Core Design Contradiction:

Adaptability or versatilityVSStability of the object's composition

Solution Approach 1:

Inventive Principle:

Principle #10Preliminary action

Solution Approach 2:

The patent uses protective carriers or stabilizing formulations that cushion mitochondria against physical and chemical damage during ex vivo storage and circulation. This beforehand cushioning maintains mitochondrial membrane integrity and functional proteins throughout the delivery process

Inventive Principle:

Principle #11Beforehand cushioning (Prior cushioning)

Data Source

PatentUS12403160B2Injection composition containing isolated mitochondria, and use thereof

Publication Date: 2025.09.02 PAEAN BIOTECH

AI summary

Provided is a composition for injection containing isolated mitochondria. More specifically, provided is a liquid composition for injection containing glycine, saccharide, buffer, and mitochondria, and a pharmaceutical composition comprising the liquid composition for injection as an active ingredient. The liquid composition for injection according to the present disclosure is capable of securing the safety of a mitochondrial therapeutic and maintaining the activity of mitochondria, by enhancing the stability of mitochondria for prevention or treatment of mitochondria-related diseases and preventing and inhibiting formation of blood clots in the blood of a subject who is administered with the same. Accordingly, the pharmaceutical composition according to the present disclosure may solve the aggregation that may occur when mitochondria are administered in the body and thus enables to safely and effectively inject mitochondria into the body to be used for the purpose of preventing and treating various diseases caused by mitochondrial dysfunction.